Aurobindo Pharma Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Q1 FY27 — transcript filed; not yet summarisedQ4 FY26
Q4 FY26 earnings call
Aurobindo Pharma reported FY26 revenue of ₹33,653 crores and EBITDA of ₹6,856 crores, both described as highest-ever, with Q4 FY26 revenue at ₹8,853 crores and EBITDA at ₹1,801 crores. Management highlighted growth across formulations, API, Europe and growth markets, alongside progress on the Pen-G backward integration, biosimilars pipeline and the TheraNym CDMO project. Executives also discussed the Lannett acquisition timeline, US business growth plans and cost pressures from power, fuel and raw material inputs.